Teva Pharmaceutical (TEVA) files Form 144 reporting proposed sales including 110,668 shares

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Limited submitted a Form 144 notice reporting proposed sales of ordinary shares by holders, including 110,668 and 33,512 shares described as "shares from rollover" and compensation-related sales. The filing lists a prior sale of 62,102 shares on 03/17/2026 with a reported value of 1,871,815.26.

Key Figures

Proposed resale (example): 110,668 shares Proposed resale (example): 33,512 shares Completed sale past 3 months: 62,102 shares +2 more

5 metrics

Proposed resale (example) 110,668 shares listed as "SHARES FROM ROLLOVER"

Proposed resale (example) 33,512 shares listed as "SHARES FROM ROLLOVER" and compensation ordinary shares

Completed sale past 3 months 62,102 shares sold on <date>03/17/2026</date>

Reported value for prior sale 1,871,815.26 monetary figure associated with 62,102-share sale

Filing date / exchange 05/01/2026 date shown with NYSE listing in excerpt

Key Terms

Form 144, shares from rollover, compensation ordinary shares, selling broker

4 terms

Form 144 regulatory

"submitted a <b>Form 144</b> notice reporting proposed sales"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

shares from rollover market

"03/03/2026 | SHARES FROM ROLLOVER | TEVA PHARMACEUTICAL"

compensation ordinary shares market

"COMPENSATION ORDINARY SHARES | 03/04/2026 | SHARES FROM ROLLOVER"

selling broker financial

"ORDINARY SHARES | CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET"

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET NEW YORK NY 10013	144180	5045122.63	1164426972	05/01/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/03/2026	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			110668	05/01/2026	COMPENSATION
ORDINARY SHARES	03/04/2026	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			33512	05/01/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Sabag Mark TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	03/17/2026	62102	1871815.26

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Teva's Form 144 filing report?

The filing reports proposed sales of ordinary shares by holders, including 110,668 and 33,512 shares. It also records a prior sale of 62,102 shares on 03/17/2026 with a reported value of 1,871,815.26, and lists broker and exchange details dated 05/01/2026.

Who is the broker listed on the Form 144 for TEVA?

The filing lists Citigroup Global Markets Inc. as the broker at 390 Greenwich Street, New York. This contact is associated with the sale processing and appears alongside exchange and date fields in the filing dated 05/01/2026.

What share amounts are noted as "shares from rollover" in the filing?

The document identifies 110,668 shares and 33,512 shares described as "shares from rollover" tied to Teva holders. These amounts are shown alongside compensation-related entries and the filing's transaction date fields.

Does the Form 144 show any completed sales in the prior three months?

Yes; the filing records a completed sale of 62,102 ordinary shares by a holder on 03/17/2026. The line item includes a monetary figure of 1,871,815.26 associated with that sale in the filing excerpt.